Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer

Vittoria Dieci, Maria; Radosevic‐Robin, Nina; Fineberg, Susan; Van den Eynden, Gert; Ternès, Nils; Penault‐Llorca, Frédérique; Pruneri, Giancarlo; M. D’Alfonso, Timothy; Demaria, Sandra; A. Castañeda, Carlos; Sanchez, Joselyn; Badve, Sunil; Michiels, Stefan; Bossuyt, Veerle; Rojo, Federico; Singh, Baljit; O. Nielsen, Torsten; Viale, Giuseppe; Kim, Seong-Rim; M. Hewitt, Stephen; Wienert, Stephan; Loibl, Sybille; L. Rimm, David; Symmans, Fraser; Denkert, Carsten; Adams, Sylvia; Loi, Sherene; Salgado, Roberto

doi:10.1016/j.semcancer.2017.10.003

Public

Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer

Published in Seminars in Cancer Biology • Oct 12, 2017

Authors:

Maria Vittoria Dieci

Nina Radosevic‐Robin

Susan Fineberg

Abstract

Morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer is gaining momentum as evidence strengthens the clinical relevance of this immunological biomarker. TILs in the post-neoadjuvant residual disease setting are acquiring increasing importance as a stratifying marker in ...

Subject

Medicine

Breast cancer

Oncology

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!